Brief: Eurocine Vaccines Expands Its Portfolio With A Therapeutic Hsv-2 Vaccine Candidate

Nidhogg Resources Holding AB (publ)

14/06/2022 15:51

June 14 (Reuters) - Eurocine Vaccines AB  EUCI.TE :
    * EUROCINE VACCINES EXPANDS ITS PORTFOLIO WITH A THERAPEUTIC
HSV-2
VACCINE CANDIDATE
    * EUROCINE VACCINES AB - ENTERED INTO A RESEARCH AND
COLLABORATION
AGREEMENT WITH REDBIOTEC AG
    * EUROCINE VACCINES AB - DEAL GIVES EXCLUSIVE GLOBAL RIGHTS
TO
DEVELOP, MANUFACTURE, COMMERCIALIZE HSV-2 VACCINE, BASED ON
REDBIOTEC'S TECHNOLOGIES
    * EUROCINE VACCINES AB - REDBIOTEC HAS A RIGHT TO ROYALTIES
ON
EUROCINE VACCINES' NET SALES OF AN APPROVED HSV-2 VACCINE,
SHOULD SUCH SALES ARISE

Source text for Eikon:  ID:nPn60ctHWa 
Further company coverage:  EUCI.TE 

 ((Reuters.Briefs@thomsonreuters.com;))